Plasma total homocysteine and carotid intima-media thickness in type 1 diabetes: A prospective study

Atherosclerosis

Volumn 236, Issue 1, 2014, Pages

  Basu, Arpita ^a   Jenkins, Alicia J ^b,c   Stoner, Julie A ^d   Thorpe, Suzanne R ^e   Klein, Richard L ^f,g   Lopes Virella, Maria F ^f,g   Garvey, W Timothy ^h   Lyons, Timothy J ^c,d  

^a OKLAHOMA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^e UNIVERSITY OF SOUTH CAROLINA   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Homocysteine; Intima media thickness; Type 1 diabetes

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; C REACTIVE PROTEIN; LIPID;

ADOLESCENT; ADULT; AMINO ACID BLOOD LEVEL; ARTERIAL WALL THICKNESS; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SMOKING; SYSTOLIC BLOOD PRESSURE; TOTAL HOMOCYSTEINE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; AGE; BLOOD; COMORBIDITY; DIABETES MELLITUS, TYPE 1; DISEASE COURSE; HYPERHOMOCYSTEINEMIA; PATHOLOGY; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; C-REACTIVE PROTEIN; CAROTID INTIMA-MEDIA THICKNESS; COMORBIDITY; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; HYPERTENSION; LIPIDS; MALE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SMOKING; YOUNG ADULT;

EID: 84905828337     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.07.001     Document Type: Article

References (43)

1. Selhub J. Homocysteine metabolism. Annu Rev Nutr 1999, 19:217-246.
2. Bostom A., Brosnan J.T., Hall B., et al. Net uptake of plasma homocysteine by the rat kidney invivo. Atherosclerosis 1995, 116:59-62.
3. Soedamah-Muthu S.S., Chaturvedi N., Teerlink T., et al. Plasma homocysteine and microvascular and macrovascular complications in type 1 diabetes: a cross-sectional nested case-control study. JIntern Med 2005, 258:450-459.
4. Wollesen F., Brattstrom L., Refsum H., et al. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int 1999, 55:1028-1035.
5. McCully K.S. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969, 56:111-128.
6. Neugebauer S., Tarnow L., Stehouwer C., et al. Total plasma homocysteine is associated with hypertension in type I diabetic patients. Diabetologia 2002, 45:1315-1324.
7. Targher G., Zenari L., Bertolini L., et al. Plasma total homocysteine levels are associated with von Willebrand factor, soluble intercellular adhesion molecule-1, and soluble tumor necrosis factor-alpha receptors in young type 1 diabetic patients without clinical evidence of macrovascular complications. Diabetes Care 2001, 24:1496-1497.
8. Lorenz M.W., Markus H.S., Bots M.L., et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007, 115:459-467.
9. Pignoli P., Tremoli E., Poli A., et al. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 1986, 74:1399-1406.
10. Dalager S., Paaske W.P., Kristensen I.B., et al. Artery-related differences in atherosclerosis expression: implications for atherogenesis and dynamics in intima-media thickness. Stroke 2007, 38:2698-2705.
11. Hofmann M.A., Lalla E., Lu Y., et al. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. JClin Invest 2001, 107:675-683.
12. Bagi Z., Ungvari Z., Szollar L., et al. Flow-induced constriction in arterioles of hyperhomocysteinemic rats is due to impaired nitric oxide and enhanced thromboxane A(2) mediation. Arterioscler Thromb Vasc Biol 2001, 21:233-237.
13. Durga J., Verhoef P., Bots M.L., et al. Homocysteine and carotid intima-media thickness: a critical appraisal of the evidence. Atherosclerosis 2004, 176:1-19.
14. Tsai M.Y., Arnett D.K., Eckfeldt J.H., et al. Plasma homocysteine and its association with carotid intimal-medial wall thickness and prevalent coronary heart disease: NHLBI Family Heart Study. Atherosclerosis 2000, 151:519-524.
15. Mazza A., Motti C., Nulli A., et al. Lack of association between carotid intima-media thickness and methylenetetrahydrofolate reductase gene polymorphism or serum homocysteine in non-insulin-dependent diabetes mellitus. Metabolism 2000, 49:718-723.
16. Becker A., Henry R.M., Kostense P.J., et al. Plasma homocysteine and S-adenosylmethionine in erythrocytes as determinants of carotid intima-media thickness: different effects in diabetic and non-diabetic individuals. The Hoorn Study. Atherosclerosis 2003, 169:323-330.
17. Polak J.F., Backlund J.Y., Cleary P.A., et al. Progression of carotid artery intima-media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes 2011, 60:607-613.
18. Lyons T.J., Jenkins A.J., Zheng D., et al. Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima-media thickness. Diabet Med 2006, 23:955-966.
19. Lopes-Virella M.F., Carter R.E., Gilbert G.E., et al. Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications. Diabetes Care 2008, 31:2006-2012.
20. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. NEngl J Med 1993, 329:977-986.
21. Nathan D.M., Lachin J., Cleary P., et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. NEngl J Med 2003, 348:2294-2303.
22. Araki A., Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. JChromatogr 1987, 422:43-52.
23. Epidemiology of Diabetes Interventions and Complications (EDIC) Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999, 22:99-111.
24. Feasibility of centralized measurements of glycated hemoglobin in the diabetes control and complications trial: a multicenter study. The DCCT Research Group. Clin Chem 1987, 33:2267-2271.
25. Held C., Sumner G., Sheridan P., et al. Correlations between plasma homocysteine and folate concentrations and carotid atherosclerosis in high-risk individuals: baseline data from the Homocysteine and Atherosclerosis Reduction Trial (HART). Vasc Med 2008, 13:245-253.
26. Hoogeveen E.K., Kostense P.J., Jakobs C., et al. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study. Circulation 2000, 101:1506-1511.
27. Perry I.J., Refsum H., Morris R.W., et al. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995, 346:1395-1398.
28. Sahakyan K., Klein B.E., Myers C.E., et al. Novel risk factors in long-term hypertension incidence in type 1 diabetes mellitus. Am Heart J 2010, 159:1074-1080.
29. Meloni G.F., Tonolo G.C., Zuppi C., et al. Hyper-homocysteinemia is not a main feature of juvenile uncomplicated type 1 diabetes. JAtheroscler Thromb 2005, 12:14-19.
30. Matteucci E., Rossi L., Mariani S., et al. Blood levels of total homocysteine in patients with type 1 diabetes (with no complications, diabetic nephropathy and/or retinopathy) and in their non-diabetic relatives. Nutr Metab Cardiovasc Dis 2002, 12:184-189.
31. Kurella Tamura M., Xie D., Yaffe K., et al. Vascular risk factors and cognitive impairment in chronic kidney disease: the Chronic Renal Insufficiency Cohort (CRIC) study. Clin J Am Soc Nephrol 2011, 6:248-256.
32. Scaglione L., Gambino R., Rolfo E., et al. Plasma homocysteine, methylenetetrahydrofolate reductase gene polymorphism and carotid intima-media thickness in Italian type 2 diabetic patients. Eur J Clin Invest 2002, 32:24-28.
33. Linnebank M., Moskau S., Farmand S., et al. Homocysteine and carotid intima-media thickness in a german population: lack of clinical relevance. Stroke 2006, 37:2840-2842.
34. Nakhai-Pour H.R., Grobbee D.E., Bots M.L., et al. Circulating homocysteine and large arterial stiffness and thickness in a population-based sample of middle-aged and elderly men. JHum Hypertens 2007, 21:942-948.
35. Babar G.S., Zidan H., Widlansky M.E. e al. Impaired endothelial function in preadolescent children wth type 1 diabetes. Diabetes Care 2011, 34:681-685.
36. Wadwa R.P., Kinney G.L., Ogden L., et al. Soluble interleukin-2 receptor as a marker for progression of coronary artery calcification in type 1 diabetes. Int J Biochem Cell Biol 2006, 38:996-1003.
37. Wotherspoon F., Laight D.W., Turner C., et al. The effect of oral folic acid upon plasma homocysteine, endothelial function and oxidative stress in patients with type 1 diabetes and microalbuminuria. Int J Clin Pract 2008, 62:569-574.
38. Ntaios G., Savopoulos C., Karamitsos D., et al. The effect of folic acid supplementation on carotid intima-media thickness in patients with cardiovascular risk: a randomized, placebo-controlled trial. Int J Cardiol 2010, 143:16-19.
39. Nanayakkara P.W., van Guldener C., ter Wee P.M., et al. Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study. Arch Intern Med 2007, 167:1262-1270.
40. Lonn E., Yusuf S., Arnold M.J., et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. NEngl J Med 2006, 354:1567-1577.
41. Bonaa K.H., Njolstad I., Ueland P.M., et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. NEngl J Med 2006, 354:1578-1588.
42. McKinley M.C., Strain J.J., McPartlin J., et al. Plasma homocysteine is not subject to seasonal variation. Clin Chem 2001, 47:1430-1436.
43. Rasmussen K., Moller J. Total homocysteine measurement in clinical practice. Ann Clin Biochem 2000, 37:627-648.